MedTrace Logo

Stereotactic Boost for Locally Advanced Non-Small Cell Lung Cancer

NCT01222572 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2015-06-04

Study results available
· View outcomes & findings →

Summary

In this research study the investigators are looking for the highest dose of a stereotactic radiation boost that can be given safely. Because stereotactic radiation is so precise, the investigators are testing whether it can be used to increase the dose to the primary tumor without significantly increasing the side effects the participant experiences; the goal is to improve the likelihood of killing the tumor.

Conditions

Interventions

RADIATION

Stereotactic boost

RADIATION

Conventional RT

DRUG

Etoposide

DRUG

Cisplatin

Sponsors & Collaborators

Principal Investigators

  • Raymond H. Mak, MD · Dana-Farber Cancer Institute/Brigham and Women's Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-12-31
Primary Completion
2012-03-31
Completion
2012-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01222572 on ClinicalTrials.gov